Adaptive Biotechnologies, Amgen Partner in Phase 3 CANDOR Trial for Multiple Myeloma
Adaptive Biotechnologies has partnered with Amgen to use Adaptive’s NGS-based clonoSEQ Assay in a Phase 3 clinical trial led by Amgen to…
News
Janssen Submits New Application to EMA for Darzalex Combo
Janssen Pharmaceuticals recently submitted a Type 2 variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for…
Poseida Developing CAR T-cells to Replace Risky Stem Cell Transplant Pre-treatments
Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem…
Janssen to Share Updates from Darzalex Studies at Hematology Meeting in Atlanta
Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American Society of Hematology (ASH) Annual…
Bluebird Bio’s CAR T-Cell Therapy Stopped Progression of Hard-to-Treat Myeloma
Initial data from a Phase 1 study of bluebird bio’s second-generation CAR T-cell therapy bb2121 for relapsed or refractory multiple myeloma showed impressive results,…
CLR 131 Continues to Show Survival Benefit in Heavily Treated Multiple Myeloma Patients
A recent update on Cellectar Biosciences’ Phase 1 trial revealed that heavily treated myeloma patients who received the lowest dose of CLR 131 survived for a…
GSK’s Investigational Therapy for Multiple Myeloma Receives Breakthrough Therapy Designation in US
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline’s investigational therapy GSK2857916 for the treatment of relapsed and refractory…
Imbruvica OK’d in Canada as Treatment for Chronic Graft-Versus-Host Disease
Health Canada has approved Imbruvica (ibrutinib) for the treatment of patients with steroid dependent or refractory chronic graft-versus-host disease (cGVHD), a life-threatening…
Poseida Awarded $19.8M Grant to Continue Developing P-BCMA-101 for Multiple Myeloma
The California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to Poseida Therapeutics to support the clinical development of their P-BCMA-101…
Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports
A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML